Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly

Med Oncol. 2009;26(1):62-6. doi: 10.1007/s12032-008-9084-9. Epub 2008 Jul 29.

Abstract

The effects of growth hormone are mediated in part by stimulating the production of insulin-like growth factor-1. Insulin-like growth factor-1 has significant effects on cell proliferation and differentiation, it is a potent mitogen, and it is a powerful inhibitor of programmed cell death (apoptosis). Insulin-like growth factor-1 also has a well-established role in the transformation of normal cells to malignant cells. Case reports on a possible association between elevated growth hormone and cancer risk in a variety of patient groups have been published. Here, we describe clinical and laboratory findings for a patient with acromegaly who first developed thyroid cancer, and then, in the follow up period, probably due to poorly controlled insulin-like growth factor-1 levels, developed a large cell non-Hodgkin's lymphoma. A search revealed that a case with these peculiarities had not previously been reported.

Publication types

  • Case Reports

MeSH terms

  • Acromegaly* / drug therapy
  • Acromegaly* / etiology
  • Adenoma / complications
  • Adenoma / metabolism*
  • Adenoma / surgery
  • Aged
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cabergoline
  • Cyclophosphamide / therapeutic use
  • Ergolines / therapeutic use
  • Human Growth Hormone / analogs & derivatives
  • Human Growth Hormone / metabolism
  • Human Growth Hormone / therapeutic use
  • Humans
  • Insulin-Like Growth Factor I / metabolism*
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / metabolism*
  • Male
  • Neoplasms, Multiple Primary*
  • Octreotide / therapeutic use
  • Prednisone / therapeutic use
  • Thyroid Neoplasms / complications
  • Thyroid Neoplasms / metabolism*
  • Thyroid Neoplasms / surgery
  • Thyroidectomy
  • Thyroxine / therapeutic use
  • Vincristine / therapeutic use

Substances

  • Antineoplastic Agents, Hormonal
  • Ergolines
  • Human Growth Hormone
  • Vincristine
  • Insulin-Like Growth Factor I
  • Cyclophosphamide
  • Cabergoline
  • pegvisomant
  • Thyroxine
  • Octreotide
  • Prednisone

Supplementary concepts

  • COP protocol 2